SOURCES SOUGHT
66 -- Upgrade Thermo Scientific ExactivePlus System to Q Exactive System
- Notice Date
- 4/14/2014
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 3900 NCTR Road, HFT-320, Bldg 50 | Rm 421, Jefferson, Arkansas, 72079, United States
- ZIP Code
- 72079
- Solicitation Number
- 1130284
- Archive Date
- 5/6/2014
- Point of Contact
- Virginia C. House, Phone: 8705437405
- E-Mail Address
-
virginia.house@fda.hhs.gov
(virginia.house@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- MARKET RESEARCH PURPOSES ONLY NOT A REQUEST FOR PROPOSAL OR SOLICITATION Part I: General Information (Introduction/Background/Scope) The U.S. Food and Drug Administration (FDA), is conducting market research to support the Center for Biologics Evaluation and Research (CBER) Facility for Biotechnology Resources (FBR). FBR provides an array of services, including the synthesis of oligonucleotides and peptides for scientists at CBER and the Center for Drug Evaluation and Research (CDER). These oligonucleotides and peptides are utilized in research ranging from gene amplification, DNA sequencing, studies of protein-protein interactions, vaccine development, etc. Crude oligonucleotides and peptides synthesized at FBR need to be purified for most applications. A liquid chromatography-mass spectrometry (LC-MS) system (ExactivePlus of Thermo Scientific) is used to confirm the molecular weights of synthetic products. The system however could be utilized to provide proteomic service by added functions of ion isolation and ion fragmentation for an analyte. The upgrading of ExactivePlus to Q Exactive will achieve this goal and expand the service provided by FBR; therefore purchase of upgrading components for converting ExactivePlus to Q Exactive Mass Spectrometry System is required. II. Objectives: Scientists at CBER and CDER conduct cutting-edge molecular biological research and review products related to pathogen identification, disease mechanisms, vaccine development (e.g., influenza and other viruses), safety of blood products, or protocols involving cellular, tissue and gene therapies, etc. Often studies require synthetic peptides for biochemical characterizations and vaccine development. In experiments involving cell or animal models, an important question is how cells or animals respond to a specific treatment or challenging. One tool for answering such critical question is to examine the change of proteins in target cells or animals, an area of study referred as proteomics. To date, the most effective way to assess the protein profile change is by LC-MS (liquid chromatography-mass spectrometry). In this practice, proteins are digested into peptides and the peptides are subjected to electrospray ionization. The molecular weights (MW) of these peptide ions are determined, followed by fragmentation of ions to produce several daughter ions. Since the MWs of daughter ions are dependent on peptide sequences, through established software programs, it is possible to derive peptide sequences in a mixture, and to identify the proteins in the original sample where peptides are derived from. To be able to perform this highly sophisticate task, an LC-MS instrument has to be equipped with components needed for ion isolation and ion fragmentation, in addition to ion mass determination. Thus upgrading the existing LC-MS system (ExactivePlus) to a Q Exactive system is necessary, to provide proteomic service(s) and keep up with current trend in biological and biomedical investigation. This is a sources sought to determine the availability and capability of sources that can meet the requirements stated herein to upgrade existing Thermo Scientific ExactivePlus LC-MS system to Q Exactive System, and/or that can offer cost effective alternatives capable of meeting requirements listed in the Part I and Part II above. The associated North American Industry Classification System (NAICS) Code is 334516 Analytical Laboratory Instrument Manufacturing; the Small Business Size Standard is 500 employees. Part III: Technical Requirements: Upgrades to existing ExactivePlus LC-MS system to Q Exactive System: i) Hardware needed to enable MS2 function (ion isolation and fragmentation) capability from MS1 function (ion mass determination). Replace Q1 rod with the hyperbolic quadrupoles inside the mass spectrometer. ii) Add advanced active beam guide to improve uptime and reduced noise, and increase robustness. iii) Provide Nanospray Flex Ion Source kit for ion generation under extreme low flow rate (nano flow). iv) Include all labor required and certification of the instrument. A. Deliverables: Site Upgrade, End Product - Thermo Scientific Q Exactive System. B. Service Requirements: Not less than a 1-year Warranty including parts and labor Yearly service agreement for preventive and corrective maintenance beyond warranty period with up to four (4) 1-year options. C. Delivery/Performance Address: Center for Biologics Evaluation and Research U.S. Food and Drug Administration 29 Lincoln Drive, Room 205 Bethesda, MD 20892 Part IV: Instructions to Prospective Respondents Responses to this sources sought shall unequivocally demonstrate that respondent can meet technical requirements for the intended purposes discussed above and/or that can provide cost effective alternatives. Though the target audience is small business firms capable of upgrading the existing Thermo Scientific ExactivePlus System to a Q Exactive system or otherwise capable of providing alternative cost effective solutions, all parties, small or large, may respond. At a minimum, responses shall include the following: • Business name and bio, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, 8(a), SDB, WOSB, EDWOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address; • Past performance information for sales of comparable instruments, to include description (technical literature and specifications), dollar value, client name, address, point of contact (POC), POC phone number and email address, and name of the manufacturer (to include DUNS number and size status) if not the respondent; • Descriptive literature, brochures, specifications, marketing material, etc. detailing the nature of products the responding firm is regularly engaged in providing. • If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this requirement; • Although this is not a request for quote, informational pricing is encouraged; • The Government encourages any comments and/or suggestions from any interested party regarding this requirement. While the Government will not respond directly to your comments and/or suggestions; we will consider them as we finalize the specifications in preparation for the forthcoming solicitation. The Government is not responsible for locating or securing any information, not identified in the response. Interested Parties must respond with capability statements which are due in person, by postal mail or email to the point of contact listed below on or before April 21, 2014 by 1:00 PM (Central Time) at the Food and Drug Administration, FDA/OO/OFBA/OAGS/DAP ATTN: Virginia C. House, 3900 NCTR Road, Bldg 50/Room 432, HFT‐320, Jefferson, AR 72079‐9502 or email virginia.house@fda.hhs.gov. Reference #1130284 in all correspondence with the point of contact listed above. Notice of Intent Responses to this sources sought announcement will assist the Government in determining whether this requirement should be set aside for small business, made available to full and open competition or procured through other than full and open acquisition procedures. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a combined synopsis/solicitation (No. 1130781) may be published via FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/1130284/listing.html)
- Record
- SN03338109-W 20140416/140414234753-7af53693f9d8d491380a3d0e029a5f54 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |